Market open
Femasys/$FEMY
Femasys shares are trading lower after the company reported a Q1 loss that missed revenue estimates.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Ticker
$FEMY
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
70
ISIN
US31447E1055
Website
Femasys Metrics
BasicAdvanced
$31M
-
-$0.85
-2.55
-
Price and volume
Market cap
$31M
Beta
-2.55
52-week high
$1.76
52-week low
$1.06
Average daily volume
228K
Financial strength
Current ratio
0.935
Quick ratio
0.459
Long term debt to equity
65.878
Total debt to equity
322.957
Interest coverage (TTM)
-11.09%
Management effectiveness
Return on assets (TTM)
-55.30%
Return on equity (TTM)
-182.18%
Valuation
Price to revenue (TTM)
15.719
Price to book
11.66
Price to tangible book (TTM)
12
Price to free cash flow (TTM)
-1.262
Growth
Revenue change (TTM)
51.97%
Earnings per share change (TTM)
-8.75%
3-year revenue growth (CAGR)
11.36%
3-year earnings per share growth (CAGR)
-9.05%
Femasys News
AllArticlesVideos
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
GlobeNewsWire·20 hours ago
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
GlobeNewsWire·1 month ago
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Femasys stock?
Femasys (FEMY) has a market cap of $31M as of May 09, 2025.
What is the P/E ratio for Femasys stock?
The price to earnings (P/E) ratio for Femasys (FEMY) stock is 0 as of May 09, 2025.
Does Femasys stock pay dividends?
No, Femasys (FEMY) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Femasys dividend payment date?
Femasys (FEMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Femasys?
Femasys (FEMY) has a beta rating of -2.55. This means that it has an inverse relation to market volatility.